Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
August 15, 2022 at 05:00 pm
Share
Theralink Technologies, Inc. reported earnings results for the third quarter and nine months ended June 30, 2022. For the third quarter, the company reported sales was USD 0.164213 million compared to USD 0.278925 million a year ago. Net loss was USD 1.71 million compared to USD 1.23 million a year ago.
For the nine months, sales was USD 0.262688 million compared to USD 0.415029 million a year ago. Net loss was USD 5.06 million compared to USD 4.01 million a year ago.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
THERALINK TECHNOLOGIES, INC. 